- TheStreet.com•44 minutes ago
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
- Motley Fool•5 hours ago
Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi await big FDA decisions in May.
- Reuters•2 days ago
The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday. AML is a cancer that originates in the bone marrow and progresses rapidly, resulting in an abnormal increase in white blood cells. Rydapt is approved to be used along with chemotherapy to treat adults newly diagnosed with AML and carrying a specific genetic mutation called FLT3, the FDA said.
NVS : Summary for Novartis AG - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||76.60 - 77.04|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.96|
|Dividend & Yield||2.72 (3.71%)|
|1y Target Est||N/A|